Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Only patients with localized lung cancer benefit from curative resection. Curative radiotherapy is recommended in patients with a resectable tumor in whom surgery is precluded for medical reasons. Adjuvant preoperative or postoperative therapy of any type does not improve the results of surgery except in patients with Pancoast tumor. Therapy for nonlocalized tumors does not affect survival. Radiotherapy has a palliative effect in 50 to 75 per cent of patients presenting with symptoms from either a primary lesion or metastases and should therefore be recommended in symptomatic patients. The palliative effect of chemotherapy is limited in lung cancers other than small cell carcinomas. However, chemotherapy alone or in association with radiotherapy produces remarkable tumor regression and some improvement of survival in small cell carcinoma. The use of immunotherapy in the treatment of lung cancer is still under evaluation.
 ...
PMID:Lung cancer. 7 94

Levels of carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), ferritin and alpha 2-pregency associated glycoprotein (alpha-2-PAG) were determined in patients with confirmed lung cancer at the time of diagnosis and in serial determinations during and after radio- or chemotherapy. Whereas AFP levels were not elevated in patients with lung cancer, increased levels of CEA, ferritin and alpha-2-PAG were found in more than 50% of the patients. The results suggest that determination of CEA, ferritin and alpha-2-PAG in the serum of patients with lung cancer may be useful to detect metastases or recurrences and to monitor the results of treatment. Furthermore, in this study CEA and ferritin could be demonstrated in extracts of lung tumor tissues by specific antisera.
 ...
PMID:Carcinoembryonic antigen, alpha 1-fetoprotein, ferritin, and alpha 2-pregnancy associated glycoprotein in the serum of lung cancer patients and its demonstration in lung tumor tissues. 7 56

Oat cell carcinoma is the one variety of primary lung cancer which is sufficiently responsive to a variety of drugs and drug combinations that a very high rate of response and significant prolongation of survival can be consistently achieved. The question of whether anyone has been "cured" by drug treatment awaits more study and the passage of time. Progress in the treatment of the other varieties of bronchogenic carcinoma is less encouraging. There is only the hope that more fundamental knowledge about the nature of the disease will bring greater progress.
 ...
PMID:Chemotherapy for lung cancer. 7 40

Aryl-hydrocarbon-hydroxylase (A.H.H.) inducibility has been studied in the peripheral-blood lymphocytes of patients with squamous-cell lung cancer, of patients with cancer at other sites, and of controls matched for age, sex, social class, and smoking habits. The proportion of high inducers was significantly greater among patients with lung cancer (but not patients with other cancers) than among controls, which suggests that, besides smoking, a constitutional factor may be involved in the pathogenesis of lung cancer.
 ...
PMID:Aryl-hydrocarbon-hydroxylase inducibility in patients with cancer. 7 21

Tumour-specific immunity to pancreatic tumour antigens, assayed by an automated tube leucocyte-adherence inhibition assay (L.A.I.), was detected in 3 of 3 patients with localised pancreatic cancer and 3 of 8 patients with more extensive pancreatic cancer. Leucocytes from pancreatic cancer patients with L.A.I. reactivity did not react to antigens of stomach, colon, or lung tumours; leucocytes from patients with stomach, colon, or lung cancer of inflammatory disease of the pancreas and bowel did not show L.A.I. reactivity to pancreatic tumour antigens.
 ...
PMID:Leucocyte adherence inhibition for detecting specific tumour immunity in early pancreatic cancer. 7 38

The relationship between incidence of lung cancer and the volume of traffic as indicated by auto exhaust concentration was examined; the results, though suggestive, did not yield consistent evidence of the association between them. Traffic jams in Nagoya began 15 years ago, a period that may not be long enough to provide definitive data on the incidence of lung cancer. The high standardized mortality ratio (SMR) of lung cancer was observed in cities with a population of less than 1 million and guns (rural areas) along the coast, although those in the metropolitan areas with populations of more than 1 million were average. The SMR did not correlate with various socioeconomic conditions and industrial air pollution. Meteorologic or geologic conditions and ocean currents were not associated with SMR of lung cancer by city and gun. The population of a gun or of some cities was not large enough to be statistically significant, and the mortality rate of lung cancer was not always stable.
 ...
PMID:Lung cancer and air pollution. 7 77

The prevalence of elevated serum levels of 5 potential tumour-associated antigens was determined in patients with lung cancer sampled at the time of initial presentation, using age- and sex-matched patients with benign lung disease as controls. Elevated levels (greater than upper 95th centile of controls) were found as follows: carcinoembryonic antigen (CEA), 17%; pregnancy-associated alpha-macroglobulin (PAM), 16%; casein 14%; human chorionic gonadotrophin (HCG) 6%; alpha-foetoprotein (AFP), 1.5%. The prevalence of elevated CEA levels (but not other markers) was higher in patients with evidence of extra-thoracic tumour spread (23%) mainly due to anaplastic tumours and adenocarcinomas. A degree of concordance of elevated marker levels occurred with CEA, HCG, casein and AFP, but there was a striking discordance of elevated CEA and PAM levels. Simultaneous assays of CEA and PAM will detect the majority of patients with elevations of any of the markers studied, and are likely to be the most useful biochemical markers in following the response of lung tumours to therapy.
 ...
PMID:Serum biochemical markers in lung cancer. 7 72

Low pH elution techniques were used on lung cancer tissues and pleural effusions of lung cancer patients to dissociate antigen-antibody complexes. The immunoglobulins obtained were assayed by indirect immunofluorescence against tissue cultures and fresh cell suspensions of various target cells; they reacted positively, in significant titers, with cells of squamous cell carcinomas and adenocarcinomas of the lung but not with cells of normal adult and fetal lung or of nonpulmonary tumors. Immunoglobulins, similarly dissociated from tumor effusions of other organs, showed no reactivity in indirect immunofluorescence tests against lung carcinoma cells.
 ...
PMID:Lung carcinoma-reactive antibodies isolated from tumor tissues and pleural effusions of lung cancer patients. 7 56

As bleomycin has up to now proved effective when used alone, the main thrust of current clinical investigations predominantly concerns its use in combination with other drugs. This has occurred along three broad patterns: 1) combination with vinca alkaloids which has been mainly in testicular carcinoma; 2) as part of multidrug regimens where bleomycin added for its lack of myelosuppression. This has occurred in the malignant lymphomas, lung cancer, and head and neck cancer; 3) in combination with radiotherapy which has taken place mostly in head and neck cervix cancer. To date, the combination of velban and bleomycin has had a major impact in improving the ability to induce complete remissions in advanced testicular carcinoma. Other drugs such as cis-platinum diaminedichloride and actinomycin D have been added and no definitive combination has been established. In the lymphomas the addition of bleomycin to the MOPP or CVP regimen has given higher complete response rates, but long-term survival data are still awaited.
 ...
PMID:A review of the bleomycin experience in the United States. 8 99

The 49 patients with squamous cell type of cervical, lung, esophagus and head and neck cancers were treated with a sequential combination of bleomycin (BLM) and mitomycin C (MMC) as follows; 5 mg of BLM daily for 5 or 7 days followed by a single injection of 10 mg of MMC on day 6 or day 8. After one week of rest period, this course was repeated two to five times depending on the response or adverse effects. For cervical cancer, 17 patients out of 18 (94%) responded with complete remission (CR) in 13 (72%) and partial remission (PR) in 4 (22%). For lung cancer, four patients out of five responded. In two of the responders, metastatic tumors disappeared completely, but primary tumors decrease to about 10% in volume. For esophagal cancer, one patient out of 3 had CR after combining the BLM and MMC treatment with radiotherapy. For head and neck cancer, these were some differences in the response rates between two hospitals. In one hospital, 12 patients out of 22 (53%) responded, with CR in 4 (18%), whereas in the other hospital, 10 patients out of 11 (94%) responded, including eight with CR (72%). Regarding the toxicity, the overall incidence was very low, although lung complications were frequent. These results are promising with hopeful prospects for the control of advanced squamous cancers with metastasis.
 ...
PMID:A sequential combination of bleomycin and mitomycin C in the treatment of advanced squamous cancers. 8 1


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>